Understanding Agilent's 1.2% Stock Increase After Earnings Report

Agilent Technologies and Recent Stock Movement

It has been some time since the last earnings report for Agilent Technologies (A). Over this period, shares have shown an increase of about 1.2%, which is slightly below the performance of the S&P 500 index. This prompts the question: will this positive trend persist until the next earnings release, or could Agilent be facing a decline?

Let's delve into the recent performance of Agilent and analyze how analysts and investors are reacting in light of this latest earnings report.

An Overview of Agilent's Q3 Earnings

In its third-quarter fiscal 2024 earnings report, Agilent Technologies posted earnings of $1.32 per share, surpassing analysts' expectations by 5.6%. However, this figure reflects an 8% decrease compared to the same period last year.

Agilent's revenues totaled $1.58 billion, exceeding the expected $1.56 billion. However, it marks a decline of 5.6% year over year, with a 4.4% drop based on core metrics. This decline stems from widespread weaknesses across several sectors including Pharmaceuticals, Food, Chemicals, and advanced materials, in addition to Academic and Government markets.

A sluggish performance in the Chinese market has further added to these concerns. Despite these challenges, Agilent noted positive movement in the Diagnostics, Clinical, and Environmental sectors during the reported quarter.

Segment Performances at Agilent

Agilent categorizes its revenue into three main segments: Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).

LSAG: This segment generated $782 million, making up 50% of total revenues. It experienced an 8% decline on a reported basis and 7% on a core basis compared to the prior year, primarily because of decreased activity in the instrument sector and weakening performance across various regions, with the exception of Environmental and Forensics, which remained steady.

ACG: This segment recorded revenues of $411 million, or 26% of total revenues, which surpassed expectations of $385 million. There was a 4% growth year over year in reported figures and a 5% rise on a core basis, mainly boosted by strong service contract revenue and positive trends in most regions, except for China.

DGG: This segment saw revenues decrease by 9% on a reported basis and 8% on a core basis, totaling $385 million, which represents 24% of total revenues. This figure was better than the anticipated $332 million, though the declining trends in Genomics and Cell Analysis posed challenges.

Company Operations and Margins

In fiscal Q3, Agilent's LSAG margin increased by 10 basis points to 60.2%. Meanwhile, ACG’s margin showed a significant enhancement by 120 basis points to 52.1%, and DGG’s margin, however, fell by 170 basis points to 51.8% year over year.

Research and Development (R&D) expenditures rose to $127 million, marking a 7.6% increase from the last year, while Selling, General and Administrative (SG&A) expenses decreased to $395 million, a 2.9% drop. As a proportion of revenues, R&D costs grew by 90 basis points to 8%, with SG&A rising by 70 basis points to 25%.

Overall operating margin for this quarter was an impressive 21.1%, up from 7.9% in the previous year. Examining segment performance, LSAG's operating margin decreased by 260 basis points to 28.4%, while ACG's improved by 130 basis points to 34%, but DGG's margin fell by 440 basis points to 18.3%.

Current Financial Health

As of the end of July 2024, Agilent's cash and cash equivalents reached $1.78 billion, up slightly from $1.67 billion in April 2024. Accounts receivable stood at $1.23 billion, down modestly from $1.25 billion from the second quarter of 2024.

Agilent's long-term debt was stable, reporting $2.137 billion compared to $2.136 billion at the previous quarter.

Future Guidance from Management

Looking ahead, Agilent's management anticipates Q4 revenues to range from $1.641 billion to $1.691 billion, projecting a decrease of up to 2.8% or slight growth up to 0.2% compared to year-ago results. Non-GAAP earnings per share for the fiscal fourth quarter are expected to be between $1.38 and $1.42.

For the full fiscal year 2024, revenue is now estimated to be between $6.45 billion and $6.50 billion, indicating a decline ranging from 5.6% to 4.9% on a reported basis and 5% to 4.3% on a core basis, compared to fiscal 2023. The non-GAAP fiscal 2024 earnings guidance has also been updated from the previous $5.15 to $5.25 to new figures of $5.21 to $5.25.

Analysts' Estimate Movements

In recent weeks, investors have noted a decline in the movement of income estimates.

Understanding Agilent's VGM Scores

As of now, Agilent holds an average Growth Score of C, reflecting a steady performance. Similarly, the stock maintains a Momentum Score of C. Conversely, the stock has received a D for its Value Score, which places it in the lower 40% for value investing strategies.

In total, Agilent carries an aggregate VGM Score of D, which should capture the attention of interested investors, especially if they are not dedicated to a specific investment strategy.

Overall Outlook For Agilent

Estimates are generally trending downward, indicating a potential shift in sentiment regarding Agilent's performance. Currently, with a Zacks Rank of #3 (Hold), the expectation is for the stock to produce an in-line return over the coming months.

Frequently Asked Questions

1. Why has Agilent's stock price increased recently?

Agilent's stock increased by 1.2% following better-than-expected earnings performance, despite challenges in key markets.

2. What were Agilent's recent earnings results?

Agilent posted earnings of $1.32 per share, beating expectations while showing a year-over-year decline.

3. How did Agilent's different segments perform?

LSAG and DGG segments experienced declines, while ACG showed growth, outperforming expectations.

4. What is Agilent's guidance for the upcoming quarter?

Agilent expects revenues between $1.641 billion to $1.691 billion for the upcoming quarter, indicating cautious optimism amid challenges.

5. What does the VGM score indicate for Agilent?

Agilent holds a D VGM score overall, suggesting it struggles against value investment criteria and is in the bottom 40% for this strategy.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.